KRAS gene mutations are found at high rates in colon cancer, pancreatic cancer, lung cancer and leukaemias. Studies show that colorectal tumours that express the KRAS gene mutation do not respond to the epidermal growth factor inhibiting drugs cetuximab (Erbitux) or panitumumab (Vectibix).